

Human CellExp™ FOLR2, human recombinant

CATALOG #: 7471-10 10 µg
7471-50 50 µg

ALTERNATE NAMES: FOLR2, FOLR-2, BETA-HFR, FBP/PL-1, FR-BETA, FR-P3, Folate-receptor-beta.

SOURCE: HEK 293 cells (Thr 17 – His 228)

PURITY: ≥ 95% by SDS-PAGE gel

MOL. WEIGHT: This protein is fused with 6xhis tag at the C-terminus and has a calculated MW of 26 kDa expressed. The predicted N-terminus is Thr17. Protein migrates as 30-33 kDa in reduced SDS-PAGE resulting from glycosylation.

ENDOTOXIN LEVEL: <1 EU/µg by LAL method

FORM: Lyophilized

FORMULATION: Lyophilized from 0.22 µm filtered solution in PBS, pH 7.4. Normally Mannitol or Trehalose is added as protectants before lyophilization.


STORAGE CONDITIONS: Store at -20°C. After reconstitution, aliquot and store at -20°C and use within 3 months. Avoid repeated freezing and thawing cycles.

RECONSTITUTION: Centrifuge the vial prior to opening. Reconstitute in sterile PBS, pH 7.4 to a concentration of 50 µg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 month. For extended storage, it is recommended to store at -20°C.

DESCRIPTION: Folate receptor beta, also known as Folate receptor 2, FBP, FOLR2, BETA-HFR, FBP/PL-1, FR-BETA, FR-P3, and is a member of the folate receptor (FOLR) family which mediates delivery of 5-methyltetrahydrofolate to the interior of cells. This protein has a 68% and 79% sequence homology with the FOLR1 and FOLR3 proteins, respectively. The FOLR2 protein was originally thought to exist only in placenta, but is also detected in spleen, bone marrow, and thymus. FOLR2 is predominantly expressed in placenta, cells of the neutrophilic lineage, and some CD34+ hematopoietic progenitor cells. It is upregulated on myeloid leukemias, head and neck squamous cell carcinomas, and several nonepithelial cancers. It is also upregulated on macrophages and monocytes

at chronic inflammatory sites including rheumatoid arthritis synovium and glioblastoma. FOLR2 is a marker for macrophages generated in the presence of M-CSF, but not GM-CSF. Its expression correlates with increased folate uptake ability. Folate conjugates of therapeutic drugs are a potential immunotherapy tool to target tumor-associated macrophages.

BIOLOGICAL ACTIVITY: Measured by its binding ability in a functional ELISA. When Folic Acid Bovine Serum Albumin was coated at 5 µg/ml (100 µl/well), the concentration of rhFOLR2 that produces 50% of the optimal binding response was found to be approximately 0.15-1.1 nM.



RELATED PRODUCTS:

- Human Recombinant DHFR (Cat. No. 6382-100)
- Mouse Recombinant DHFR (Cat. No. 6383-100)
- Human CellExp™ FOLR1, human recombinant (Cat. No. 7456-10, -50)
- Human CellExp™ FOLR1, mouse recombinant (Cat. No. 7457-10, -50)

FOR RESEARCH USE ONLY! Not to be used in humans.

